Thread by @ASPphysician, Inhaled budesonide. A thread.There has been a lot of energy being given [...]

Inhaled budesonide. A thread.

There has been a lot of energy being given to budesonide in COVID-19, with some tweeterati referring to it as having "strong evidence".

Also, FPs/ED MDs would love a Rx that works!

It merits discussion.
Let me explain (long thread alert) ...

There are 2 RCTs available on inhaled corticosteroids:
STOIC ( https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext#.YIqiWU0BDYU.twitter">https://www.thelancet.com/journals/... and https://clinicaltrials.gov/ct2/show/NCT04416399)">https://clinicaltrials.gov/ct2/show/... and PRINCIPLE ( https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1">https://www.medrxiv.org/content/1... and https://www.isrctn.com/ISRCTN86534580 )

I">https://www.isrctn.com/ISRCTN865... will start off by saying what we know about systemic corticosteroids in patients with COVID:

Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community:...

BACKGROUND Inhaled budesonide has shown efficacy for treating COVID-19 in the community but has not yet been tested in effectiveness trials. METHODS We performed a multicenter, open-label, multi-arm,...

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00160-0/fulltext#.YIqiWU0BDYU.twitter

They likely work and save lives if patients need supplemental O2 or supported ventilation. The strongest evidence comes from the massive RECOVERY trial (N=6435, https://www.nejm.org/doi/full/10.1056/NEJMoa2021436).">https://www.nejm.org/doi/full/... Importantly, dexamethasone appeared potentially harmful for patients not requiring O2.

I& #39;m always reluctant to invoke mechanistic approaches—because they are so often wrong—but we know that early in disease virus is main player and, as disease progresses, inflammation is the problem.
The results of antiviral & anti-inflammatory studies are consistent w/this.

But maybe systemic steroids aren& #39;t beneficial early on because systemic toxicity outweighs any benefit. I can buy this, which is why we need RCTs to evaluate this.

These studies were also prompted by observation early on that pts w/COPD, asthma underrepresented in cases.

STOIC:

Adults in Oxfordshire, UK
Strat by age, sex, comorbid
Phase 2
New-onset (<8d) COVID symptoms
Budesonide inh 400mcg bid up to 28d vs. usual care (i.e. unblinded, advised to take antipyretics for fever and honey for cough)
n=146, mean age 44.5
1o outcome: 28d urgent care/ED visit

ITT Results: 11 (15%) in usual care, 2 (3%) budesonide group.
Sounds great, right? NNT=8!
Clinical recovery: 1d shorter
No diff. in SaO2 or viral load
Study stopped early because "outcome would not change with further participant enrolment".

Sampling of 1o: DKA, AKI, ?rib trauma

Why was study halted? Reduced recruitment after national lockdown, vaccination, and "ethical consideration of the primary outcome".
Funding: NIHR and AstraZeneca

Make your own conclusion, but unblinded, small study, with no substantial and convincing evidence of real pt. benefit

So let& #39;s look at PRINCIPLE, an open-label, adaptive platform
Adults in UK, recruited in Primary Care
≥65 or ≥50 w/comorbidities
New-onset (<14d) COVID symptoms
Not all PCR+
Budesonide inh 800mcg bid x 14d vs. azithro, doxy (1st 17d), colchicine (last 27d), or usual care.

1o outcome: initially hosp/death --> time to pt. self-reported "feeling recovered" and hosp/death d/t COVID.
Recovery used Bayesian exponential model (regressed on Rx and stratification), including parameters for temporal drift. @DrToddLee
Hosp/death didn& #39;t incl. temporal drift.

Trial was stopped (as with STOIC) because UK had done such a good job with public health measures and vaccination, so unlikely to get closer to answering hospitalization/death question.

Analysis is an interim analysis up to March 25.
N=1032 budesonide, 1943 usual care

Analysis provided incl. only 751 (budesonide), 1028 (usual), and 643 (other) PCR+. (i.e. not an ITT)
Mean age: 63, 83% with comorbidities.
Time to first recovery HT 1.2 (~3 days).
8.5% (59/692) vs 10.3% (100/968) hospitlzn/death, but an additional 2 hospitalzn in budesonide group

Oy! What to do? It all sounded so clean at first!
But doesn& #39;t it make sense to give budesonide to all?
1. We have done this "what harm could it cause" before with hydroxychloroquine, ivermectin, etc. (Guess what, it caused problems)
2. There is reason to believe ...

that inhaled steroids increase risk of bacterial pneumonia. ( https://www.bmj.com/content/363/bmj.k4388).">https://www.bmj.com/content/3... Relevant with short duration? Dunno.
Also, at least in UK, inh steroids was actually associated w/worse outcomes not better: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30415-X/fulltext#.YIrLr7Qf5MU.twitter">https://www.thelancet.com/journals/...

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma...

Our results do not support a major role for regular ICS use in protecting against COVID-19-related death among people with asthma or COPD. Observed increased risks of COVID-19-related death can be...

https://www.bmj.com/content/363/bmj.k4388

I understand why Family and ED physicians, and patients, are reaching for inhaled steroids. Esp. because there is so little to offer.

My advice: don& #39;t—the evidence of benefit is so weak, and there is more than a remote possibility of harm.
@MPaiMD

Latest Threads Unrolled: